ArticleThe Journal of investigative dermatology2013
Topical antihistamines display potent anti-inflammatory activity linked in part to enhanced permeability barrier function.
Article in The Journal of investigative dermatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03728569 (Skin Barrier Dysfunction and the Role of Skin Barrier Restoration on Cutaneous and Systemic Inflammation in the Aged Population), which is not on this map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Skin Barrier Dysfunction and the Role of Skin Barrier Restoration on Cutaneous and Systemic Inflammation in the Aged Population
Who cites it
31 citing papers in PubMed, 65 citations in OpenAlex.
- Macrophages: Subtypes, Distribution, Polarization, Immunomodulatory Functions, and Therapeutics.MedComm · 2025Review
- Review of sensory systems deployed by epidermal keratinocytes.Frontiers in cell and developmental biology · 2025Review
- Itch and Pain Behaviors in Irritant Contact Dermatitis Produced by Sodium Lauryl Sulfate in Mice.International journal of molecular sciences · 2024Article
- Benefits of topical natural ingredients in epidermal permeability barrier.Frontiers in physiology · 2023Review
- Improvement in Cutaneous Conditions Can Benefit Some Health Conditions in the Elderly.Clinical interventions in aging · 2023Article
- Effects of mucopolysaccharide polysulphate on tight junction barrier in human epidermal keratinocytes.Experimental dermatology · 2022Article
- Optimizing emollient therapy for skin barrier repair in atopic dermatitis.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2022Review
- Irritant Contact Dermatitis - a Review.Current dermatology reports · 2022Review
- Mutations in 3β-hydroxysteroid-δ8, δ7-isomerase paradoxically benefit epidermal permeability barrier homeostasis in mice.Experimental dermatology · 2021Article
- Both Prevalence and Severity of Pruritus are Associated with Age in Chinese Patients with Skin Diseases.Clinical, cosmetic and investigational dermatology · 2021Article
- Histamine 2 Receptor Agonism and Histamine 4 Receptor Antagonism Ameliorate Inflammation in a Model of Psoriasis.Acta dermato-venereologica · 2020Article
- Review
- Role of Resveratrol in Regulating Cutaneous Functions.Evidence-based complementary and alternative medicine : eCAM · 2020Review
- Association between lactic acid sting test scores, self-assessed sensitive skin scores and biophysical properties in Chinese females.International journal of cosmetic science · 2019Article
- A topical heparinoid-containing product improves epidermal permeability barrier homeostasis in mice.Experimental dermatology · 2019Article
- Review
- Non-invasive Approaches for the Diagnosis of Autoimmune/Autoinflammatory Skin Diseases-A Focus on Psoriasis andFrontiers in immunology · 2019Review
- Anti-Inflammatory and Skin Barrier Repair Effects of Topical Application of Some Plant Oils.International journal of molecular sciences · 2017Review
- Epidermal Dysfunction Leads to an Age-Associated Increase in Levels of Serum Inflammatory Cytokines.The Journal of investigative dermatology · 2017Article
- Comparison of the Efficacy of Atopalm(®) Multi-Lamellar Emulsion Cream and Physiogel(®) Intensive Cream in Improving Epidermal Permeability Barrier in Sensitive Skin.Dermatology and therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 7 countries.
Funding
Abstract
Systemic antagonists of the histamine type 1 and 2 receptors (H1/2r) are widely used as anti-pruritics and central sedatives, but demonstrate only modest anti-inflammatory activity. Because many inflammatory dermatoses result from defects in cutaneous barrier function, and because keratinocytes express both Hr1 and Hr2, we hypothesized that H1/2r antagonists might be more effective if they were used topically to treat inflammatory dermatoses. Topical H1/2r antagonists additively enhanced permeability barrier homeostasis in normal mouse skin by the following mechanisms: (i) stimulation of epidermal differentiation, leading to thickened cornified envelopes; and (ii) enhanced epidermal lipid synthesis and secretion. As barrier homeostasis was enhanced to a comparable extent in mast cell-deficient mice, with no further improvement following application of topical H1/2r antagonists, H1/2r antagonists likely oppose mast cell-derived histamines. In four immunologically diverse, murine disease models, characterized by either inflammation alone (acute irritant contact dermatitis, acute allergic contact dermatitis) or by prominent barrier abnormalities (subacute allergic contact dermatitis, atopic dermatitis), topical H1/2r agonists aggravated, whereas H1/2r antagonists improved, inflammation and/or barrier function. The apparent ability of topical H1r/2r antagonists to target epidermal H1/2r could translate into increased efficacy in the treatment of inflammatory dermatoses, likely due to decreased inflammation and enhanced barrier function. These results could shift current paradigms of antihistamine utilization from a predominantly systemic to a topical approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.